Skip to main content
OpenTrials
Completed

NCT Number: NCT02346292

Observational Multicenter Non-interventional Study on COPD Patients Treatment Strategies at the Time of Hospital Discharge and Within 12 Months of Follow-up on an Outpatient Primary Care Basement

The study is an observational multicenter descriptive study. It is planned to enroll approximately 1250 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or therapy. The study will be conducted in approximately 20-25 institutions of treatment and prevention in Russian Federation and will include about 50 to 60 subject at each clinical site.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

COPD Chronic Disease Disease Attributes Lung Diseases Lung Diseases, Obstructive Pathologic Processes Pathological Conditions, Signs and Symptoms Pulmonary Disease, Chronic Obstructive Respiratory Tract Diseases

Age range

40 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Research Site, Barnaul, Russia

Loading trial locations.

About this study

The study is an observational multicenter descriptive study. It is planned to enroll approximately 1000 subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation into departments of pulmonology or therapy. The study will be conducted in approximately 20-25 institutions of treatment and prevention in Russian Federation and will include about 50 to 60 subject at each clinical site.

This is an observational study, so there is no treatment protocol or subjects' management recommendations required. The study subjects receive medical treatment according to the routine practice for their disease in Russian Federation. A subject's participation in this clinical study should not affect character and amount of care provided according to the routine clinical practice.

The study includes 5 clinical visits: Study Enrolment Visit, Month 3 Visit, Month 6 visit, Month 9 Visit, Month 12 visit / End of Study Visit.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Signed informed consent . Men and women at least 40 years old, with smoking history more than 10 pack-years.
  • Hospitalization for the reason of COPD exacerbation (exacerbation defined as acute condition, different from typical fluctuations of general condition and requiring change of therapy).
  • Diagnosis of severe or very severe COPD based on final spirometry (performed in a standardized manner using salbutamol 400 mg), or history of diagnosis of severe or very severe COPD based on spirometry performed during 6 months before the hospitalization.

Exclusion criteria

  • Participation in any interventional study.
  • Concomitant respiratory diseases, i.e. confirmed or suspected malignancy or any other serious condition, including lung tumor, lung fibrosis, interstitial lung disease, tuberculosis, sarcoidosis.
  • Patient is unable or unwilling to complete questionnaires, unable to understand study procedures, or other reasons which, in the investigator's opinion, could affect study procedures performance.

Treatment and study plan

Primary outcomes

  1. Percentage of subjects with severe and very severe COPD who received prescription of therapy, including different schemes of inhaled glucocorticoids use, according to main principles of COPD therapy (GOLD 2014 recommendations)

    Time frame: up to 12 months

Secondary outcomes

  1. Description of social characteristics (days of disability, etc.), economical status of subjects if applicable (if patient agreed) (average monthly income) with severe and very severe COPD hospitalized for the reason of COPD exacerbation

    Time frame: at the time of 1st visit

  2. % of subjects with severe and very severe COPD for whom scheme of inhaled glucocorticoids use was changed after 3, 6, 9, and 12 months of follow-up (outpatient conditions after discharge from the hospital)

    Time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up

  3. Frequency and reasons of treatment scheme correction during follow-up after its prescription at the moment of discharge from the hospital

    Time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up

    As reasons of treatment changes and/or its correction it will be measured with:

    • Number of hospitalizations in the previous 3 months before enrollment and in 3, 6, 9, 12 months;
    • Number or emergency calls, outpatient care settings visits in the previous 3 months before enrollment and in 3, 6, 9, 12 months;
    • Number of exacerbations and number of related hospitalizations in the previous 3 months before enrollment and in 3, 6, 9, 12 months.
    • Number of pneumonia cases in the previous 3 months before enrollment and in 3, 6, 9, 12 months.

  4. % of subjects with severe and very severe COPD who during the follow-up period attended medical institution for the correction of treatment scheme prescribed at the moment of discharge from the hospital

    Time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up

  5. % of subjects with severe and very severe COPD, received treatment with short acting anticholinergic drugs, SABA, LABA, LAMA, oral CS, FDC, phosphodiesterase type 4 inhibitors, theophylline

    Time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up

  6. % of patients with asthma-COPD overlap syndrome among all subjects with severe and very severe COPD hospitalized for the reason of COPD exacerbation

    Time frame: at the time of 1st visit and 12 months of follow-up

  7. % of subjects with asthma-COPD overlap syndrome who received treatment with inhaled glucocorticoids both

    Time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up

  8. % of patients with severe and very severe COPD, who received treatment with short acting anticholinergic drugs, SABA, LABA, LAMA, oral CS, FDC, phosphodiesterase type 4 inhibitors, theophylline, among all subjects with ACOS

    Time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up

  9. EQ-5D results

    Time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up

  10. CAT results

    Time frame: at the moment of discharge and after 3, 6, 9, and 12 months of follow-up

Sponsors and collaborators

Lead sponsor

AstraZeneca

Industry

Registry information

Acronym: CLOUD

Important dates

Study start
2015
Primary completion
2016
Study completion
2016
First posted
Jan 27, 2015
Registry last updated
Dec 22, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.